Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 3, 2011, Pages 295-306

  Forcillo, Jessica ^a   Maltais, Simon ^a   Aubin, Marie Claude ^a   Shi, Yan Fen ^a   Carrier, Michel ^a   Tardif, Jean Claude ^a   Perrault, Louis P ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

coronary arteries; endothelial dysfunction; left ventricular hypertrophy; oxidative stress; statins

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; CYCLIC GMP; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRATE; NITRIC OXIDE; NITRITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCENDING AORTA; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY; DIASTOLIC DYSFUNCTION; DRUG BIOAVAILABILITY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EPICARDIUM; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHAM PROCEDURE; SWINE; VASODILATATION;

ANGIOTENSIN II; ANIMALS; AORTA; CORONARY VESSELS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ECHOCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; MALE; NITRATES; NITRITES; PYRROLES; RANDOM ALLOCATION; SWINE; VASODILATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80052718888     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182244993     Document Type: Article

References (39)

1. Shepherd J. Statin therapy in clinical practice: new developments. Curr Opin Lipidol. 1995;6:254-255.
2. Aubin MC, Carrier M, Shi YF, et al. Role of probucol on endothelial dysfunction of epicardial coronary arteries associated with left ventricular hypertrophy. JCardiovasc Pharmacol. 2006;46:702-710. (Pubitemid 44309665)
3. Virdis A, Ghiadoni L, Cardinal H, et al. Mechanism responsible for endothelial dysfunction induced by fasting hyperhomocysteinemia in normotensive subjects and patients with essential hypertension. JAm Coll Cardiol. 2001;38:1006-1015.
4. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role ofoxidant stress. Circ Res. 2000;87:840-844.
5. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vassomotion. NEngl JMed. 1995;332:488-493.
6. Vanhoutte PM, Perrault LP, Vilaine JP. Endothelial dysfunction and vascular disease. In: Rubany GM, Dzau VM, eds. Endothelium in Clinical Practice. New York: Marcel Dekker Inc; 1997:265-290.
7. Malo O, Carrier M, Shi YF, et al. Specific alterations ofendothelial signal transduction pathways of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2003;42: 275-286. (Pubitemid 36899682)
8. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22: 300-305. (Pubitemid 34127043)
9. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233. (Pubitemid 29293431)
10. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Effects ofobesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol. 2006;97:1553-1557. (Pubitemid 43737023)
11. LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/ or unstable angina pectoris. Am J Cardiol. 1995;76:474-479.
12. Susekov AV, Rozhkova TA, Tripoten' MI, et al. Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness ofvascular wall. Kardiologiia. 2007;47:25-30.
13. Susekov AV, Zubareva M, Tripoten MI, et al. Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels oflipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia. Kardiologiia. 2006;46:4-10. (Pubitemid 44608162)
14. Bots ML, Palmer MK, Dogan S, et al.; METEOR Study Group. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months oftreatment: the METEOR study. JIntern Med. 2009;265:698-707.
15. Calabro P, Yeh ETH. The pleiotropic effects ofstatins. Curr Opin Cardiol. 2005;20:541-546.
16. Patel R, Negueh SF, Tsyboeuleva N. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy Circulation. 2001;104:317-324. (Pubitemid 32666954)
17. Senthil V, Suet NC, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res. 2005;97:285-292. (Pubitemid 41105455)
18. Steinberg D. An interpretative history of the cholesterol controversy: part 1. JLipid Res. 2004;45:1583-1593. (Pubitemid 39296197)
19. Bonetti PO, Wilson SH, Rodriguez-Porcel M, et al. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. JAm Coll Cardiol. 2002;40:546-554. (Pubitemid 34833173)
20. Massaki I, Losordo DW. Statins and the endothelium. Vascul Pharmacol. 2007;46:1-9. (Pubitemid 44856372)
21. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins Arterioscler Thromb Vasc Biol. 2003;23:729-736. (Pubitemid 36566160)
22. Sodha NR, Boodhwani M, Ramlawi B, et al. Atorvastatin increases myo-cardial indices of oxidative stress in a porcine model of hypercholester-olemia and chronic ischemia. J Card Surg. 2008;23:312-320. (Pubitemid 351852564)
23. Boodhwani M, Mieno S, Feng J, et al. Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. JThorac Cardiovasc Surg. 2008:135:117-122.
24. Shi Y, Denault AY, Couture P, et al. Biventricular diastolic filling patterns after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2006;131:1080-1086.
25. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108: 1429-1437. (Pubitemid 33091980)
26. Malo O, Desjardins F, Tanguay JF, et al. Tetrahydrobiopterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model. Cardiovasc Res. 2003;59:501-511. (Pubitemid 37272044)
27. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy J Mol Cell Cardiol. 2003;35:851-859. (Pubitemid 36773597)
28. Mac Carthy PA, Shah AM. Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. Circulation. 2000;101:1854-1860. (Pubitemid 30213109)
29. Kingsbury MP, Turner MA, Flores NA, et al. Endogenous and exogenous coronary vasodilation are attenuated in cardiac hypertrophy: a morpho-logical defect? JMol Cell Cardiol. 2000;32:527-528.
30. Grieve DJ, Mac Carthy PA, Gall NP, et al. Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy. Hypertension. 2001;38:267-273. (Pubitemid 34224756)
31. Chen TH, Tseng HP, Yang JY, et al. Effects ofantioxidant in endothelial cells exposed to oxidized low-density lipoproteins. Life Sci. 1998;62:277-282.
32. Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly Africans Americans. Neurology. 2007;69: 1873-1880. (Pubitemid 350071149)
33. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65:1388-1394. (Pubitemid 41552767)
34. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40:1880-1883. (Pubitemid 44544890)
35. Takagi H, Umemoto T. Effect ofpreoperative statin therapy on postoperative atrial fibrillation in cardiac surgery. Circ J. 2010;74:2788-2790.
36. Eagle KA, Chopra V Statins before coronary procedures: a new indication for an old friend. JAm Coll Cardiol. 2010;56:1110-1112.
37. Winchester DE, Wen X, Xie L, et al. Evidence of pre-procedural statin therapy: ameta-analysisofrandomizedtrials. JAm Coll Cardiol. 2010;56; 14:1099-1109.
38. Vaduganathan M, Stone NJ, Lee R, et al. Perioperative statin therapy reduces mortality in normolipidemic patients undergoing cardiac surgery. JThorac Cardiovasc Surg. 2010;140:1018-1027.
39. Deedwania P, Singh V, Davidson MH. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol. 2009;104(suppl):3E-9E.